anifrolumab
Selected indexed studies
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus. (N Engl J Med, 2020) [PMID:31851795]
- Anifrolumab. (, 2006) [PMID:34406725]
- Anifrolumab. (, 2012) [PMID:37824693]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus. (2020) pubmed
- A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. (2023) pubmed
- Anifrolumab in systemic lupus erythematosus. (2023) pubmed
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. (2017) pubmed
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. (2023) pubmed
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. (2019) pubmed
- Anifrolumab. (2006) pubmed
- Anifrolumab. (2012) pubmed
- Anifrolumab: First Approval. (2021) pubmed
- Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. (2024) pubmed